Zhejiang Wolwo Bio-Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Gengxi Hu

İcra Kurulu Başkanı

CN¥780.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	13.8yrs
CEO sahipliği	8.3%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	7.3yrs

Son yönetim güncellemeleri

Recent updates

CEO

Gengxi Hu (60 yo)

13.8yrs

Görev süresi

CN¥780,000

Tazminat

Mr. Gengxi Hu serves as Consultant at Shanghai Creation Investment Management Co. Ltd. Mr. Hu has been Non-Independent Director at Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. since January 28, 2011 and ser...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gengxi Hu	Chairman & GM	13.8yrs	CN¥780.00k	8.35% CN¥ 969.2m
Lu Zhang	Deputy GM & Non-Independent Director	7.8yrs	CN¥780.00k	Veri yok
Ziqiang Bi	Deputy GM & Non-Independent Director	1.9yrs	CN¥780.00k	Veri yok
Yanni Chen	Non-Independent Director	13.8yrs	Veri yok	Veri yok
Guoliang Xu	Independent Director	4.8yrs	CN¥120.00k	Veri yok
Tao Jin	Chair of the Supervisory Board	7.3yrs	Veri yok	Veri yok
Huifeng Yang	Supervisor	7.3yrs	Veri yok	Veri yok
Feida Zhang	Independent Director	1.9yrs	CN¥120.00k	Veri yok

7.3yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300357 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.3 yıldır).

Zhejiang Wolwo Bio-Pharmaceutical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Executive Appointments

High number of new and inexperienced directors

Recent updates

Now 21% undervalued

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces the Profit Distribution Proposal for the Third Quarter of 2024

Third quarter 2024 earnings released: EPS: CN¥0.23 (vs CN¥0.23 in 3Q 2023)

Investor sentiment deteriorates as stock falls 19%

Now 31% undervalued

New minor risk - Share price stability

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 23%

Second quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.15 in 2Q 2023)

Dividend reduced to CN¥0.18

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Cash Dividend (Tax Included) on (A Shares) for 2023, Payable on 04 July 2024

Now 20% undervalued after recent price drop

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 1Q 2023)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 19, 2024

New minor risk - Share price stability

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.17 in 2Q 2022)

Investor sentiment improves as stock rises 18%

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 6, 2023

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves the Cash Dividend for the Year 2022

First quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.17 in 1Q 2022)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Executive Appointments

Third quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.24 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.15 in 2Q 2021)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Implements Final Profit Distribution Plan A shares for 2021, Payable on June 16, 2022

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021

Investor sentiment improved over the past week

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2021

First quarter 2022 earnings released: EPS: CN¥0.17 (vs CN¥0.14 in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.23 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.13 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.13 in 2Q 2020)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 01 June 2021

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Approves Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.079 in 1Q 2020)

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2020

New 90-day low: CN¥60.37

Full year 2020 earnings released: EPS CN¥0.53 (vs CN¥0.57 in FY 2019)

Revenue misses expectations

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥89.40

New 90-day high: CN¥77.04

New 90-day high: CN¥70.51

New 90-day high: CN¥63.10

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. announced that it expects to receive CNY 725 million in funding

Third quarter earnings released

New 90-day low: CN¥54.70

New 90-day low - CN¥57.51

Earnings released

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş